Innovative Bispecific Nanobody Targeting Transforming Protein E6 and E7 for Cervix Cancer Therapy
VHH-P371 is a next-generation humanized bispecific nanobody fusion protein specifically engineered to target Transforming protein E6 (E6) and Transforming protein E7 (E7) from human papillomavirus type 16. Currently undergoing biological testing, VHH-P371 holds excellent potential as a novel therapeutic modality for cervix cancer. By focusing on E6 and E7, two well-validated oncogenic drivers in HPV16-related malignancies, this nanobody offers a unique approach to disease intervention at the molecular level.
| Candidate | VHH-P371 |
| Target | Transforming protein E6 (E6) Transforming protein E7 (E7) |
| Modality | humanized bispecific VHH |
| Indication | Cervix Cancer |
Licensing Opportunity
VHH-P371 is currently available for out-licensing and collaborative development opportunities. We welcome inquiries from partners interested in advancing this innovative bispecific nanobody program for cervix cancer and related indications.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P371 |
Modality
VHH-P371 is a bispecific nanobody fusion protein constructed from two single-domain antibodies joined by a flexible (G4S)3 linker. The small molecular size and unique structure of this nanobody platform facilitate enhanced tissue penetration, stability, and efficient tumor targeting. The humanized format decreases immunogenicity concerns while maintaining an extended half-life. Its modular design, incorporating two distinct binding domains, enables the simultaneous targeting of multiple oncogenic pathways with high precision, presenting significant therapeutic promise for cervix cancer, especially in cases with established HPV16-driven disease.
Target
Transforming protein E6 and Transforming protein E7 are viral oncoproteins expressed primarily in epithelial cells infected with HPV16, the predominant high-risk subtype associated with cervix cancer. Both E6 and E7 disrupt key cell-cycle regulatory pathways: E6 mediates degradation of p53, while E7 inactivates retinoblastoma protein. Persistent expression of transforming protein E6 and transforming protein E7 is essential for the malignant progression of HPV16-positive tumors. As such, these proteins represent highly attractive and scientifically validated therapeutic targets within the cervix cancer landscape. VHH-P371's focused activity against transforming protein E6 and transforming protein E7 aligns with a precision medicine strategy to disrupt oncogenesis at its root molecular causes, providing notable strategic value for future cervix cancer interventions.
Mechanism of Action
VHH-P371 exerts its antiviral and anticancer effects by specifically binding to transforming protein E6 and transforming protein E7 of HPV16. This dual targeting interferes with viral replication and oncoprotein-mediated dysregulation of host pathways, aiming to restore tumor suppressor function and inhibit tumorigenic transformation. The nanobody's high affinity and structural flexibility allow for optimal engagement of intracellular targets. Furthermore, the modular nanobody platform opens the door for advanced therapeutic formats, such as bispecifics and antibody-drug conjugates, supporting versatility in both monotherapy and combination regimens for cervix cancer and related indications.
Cervix Cancer
Cervix cancer remains a significant global health challenge, ranking among the most common cancers affecting women worldwide. High-risk human papillomavirus, particularly HPV16, is the leading etiological factor. Current standard-of-care options encompass surgical intervention, radiotherapy, chemotherapy, and, increasingly, molecularly targeted therapy and immunotherapy approaches. However, these treatments are often limited by issues such as non-specific toxicity, resistance, and recurrence, leaving substantial unmet clinical needs for more selective and effective agents. Despite preventive vaccination progress, many patients continue to present with advanced or persistent disease requiring new therapeutic modalities. VHH-P371, targeting the critical viral oncoproteins responsible for malignant transformation in HPV16-positive tumors, offers a promising solution to advance precision oncology for cervix cancer patients.